Methods of treating gastrointestinal stromal tumors
AssigneeDeciphera Pharmaceuticals, LLC
InventorsRodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Claims9
A method of treating a patient suffering from Grade 2 or Grade 3 palmer-planter erythrodysesthesia syndrome while being administered 150 mg ripretinib daily or twice daily for treatment of gastrointestinal stromal tumors, comprising:
- withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome then administering to the patient 100 mg daily ripretinib for at least 28 days, if the patient is suffering from Grade 3 palmer-planter erythrodysesthesia syndrome;
- or if the patient is suffering from Grade 2 palmer-planter erythrodysesthesia syndrome, withholding administration of ripretinib until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome or baseline;
- if the patient recovers from the palmer-plantar erythrodysesthesia syndrome within 7 days of withholding administration, then administering to the patient 150 mg daily ripretinib, or if the patient has not recovered, then administering to the patient 100 mg daily ripretinib for at least 28 days.
A method of treating a patient suffering from Grade 3 palmer-plantar erythrodysesthesia syndrome while being administered 150 mg ripretinib daily or twice daily for treatment of gastrointestinal stromal tumors, comprising withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome, then administering to the patient 100 mg daily ripretinib for at least 28 days.
A method of treating a patient suffering from Grade 2 palmer-plantar erythrodysesthesia syndrome while being administered 150 mg ripretinib daily or twice daily for treatment of gastrointestinal stromal tumors comprising a) withholding administration of ripretinib until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome or baseline;
- b) if the patient recovers from the palmer-plantar erythrodysesthesia syndrome within 7 days of withholding administration, then administering to the patient 150 mg daily ripretinib or c) if the patient has not recovered, then administering to the patient 100 mg daily ripretinib for at least 28 days.
Dependencies are inferred from the claim text.